In the search for cytokines whose antiproliferative action could be enhanced by combination with dipyridamole, 2,6-bis(diethanolamino)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine, the combination of tumor necrosis factor-α (TNF-α) with this agent was evaluated in various human tumor cell lines. Inhibition of the proliferation of human melanoma cell lines MM-1CB and HMV-1 by TNF-α (1-10 2 U/ml) was enhanced in culture dishes by combination treatment with dipyridamole (0.1-10 μM). The enhancement effect was also detected in other tumor cell lines: T98 (glioma), SCC-1CB (squamous cell carcinoma), HAC-2 (ovarian clear-cell carcinoma), HLE (hepatoma), HEC-1 (endometrial adenocarcinoma) and HOC-21 (ovarian serous cystadenocarcinoma). The incorporation of [ 1 4 C]amino acids and [ 3 H]uridine into acid-insoluble cell materials in the combination-treated cells was not significantly different from that in cells treated with TNF-α or dipyridamole. However, the incorporation of [ 3 H]thymidine was specifically inhibited in all cell lines examined after more than 12 h of the TNF-α and dipyridamole combination treatment, although neither agent alone inhibited this incorporation. On the other hand, the growth of tumors induced by the injection of MM-1CB and HMV-1 cells into nude mice was more markedly inhibited by the subcutaneous administration of TNF-α in combination with orally administered dipyridamole than by either agent alone. The results presented suggested that dipyridamole is beneficial in assuring the effectiveness of anti-cancer cytokine therapy.